Avaliação Ecológica Rápida de Qualidade de Água e Bioindicadores Bentônicos no Parque Nacional da Serra do Gandarela, Minas Gerais

Durante uma disciplina de pós-graduação, realizamos uma Avaliação Ecológica Rápida sobre qualidade de água e biodiversidade de bioindicadores bentônicos no Parque Nacional (PARNA) da Serra do Gandarela, MG. Os objetivos foram: (a) capacitar profissionais na utilização de metodologias atuais em Rapid Assessment Protocols (RAP) para estudos de diagnóstico e monitoramento de integridade ecológica de ecossistemas aquáticos em regiões de cabeceira de bacias hidrográficas; (b) contribuir ao conhecimento da biodiversidade aquática em corpos d’água no PARNA Serra do Gandarela; (c) fomentar intercâmbio e colaboração entre mestrandos, doutorandos, guarda-parques, visitantes, membros de comitês de bacia, gestores ICMBio, moradores e interessados na conservação de biodiversidade no Quadrilátero Ferrífero; (d) gerar informações de base sobre qualidade de água, biodiversidade de macroinvertebrados bentônicos bioindicadores de qualidade de água no PARNA Serra do Gandarela. Os principais resultados revelam que o PARNA Serra do Gandarela é guardião de riachos de cabeceira em condições de referência, com elevada diversidade de hábitats aquáticos e ótima qualidade de água, onde vivem organismos bentônicos sensíveis, tolerantes e resistentes à poluição. Sendo a Serra do Gandarela responsável pela segurança hídrica de grande parte dos municípios do Quadrilátero Ferrífero de Minas Gerais, é extremamente importante que estes riachos em condições de referência sejam conservados e utilizados em futuros estudos de avaliação de impactos ambientais e programas de monitoramento de condições ecológicas de longo prazo. As condições de alta preservação devem servir como baliza de referência para tomadores de decisão em processos de licenciamento ambiental de empreendimentos potencialmente causadores de impactos ambientais e riscos à biodiversidade

Diretriz sobre Diagnóstico e Tratamento da Cardiomiopatia Hipertrófica – 2024

Hypertrophic cardiomyopathy (HCM) is a form of genetically caused heart muscle disease, characterized by the thickening of the ventricular walls. Diagnosis requires detection through imaging methods (Echocardiogram or Cardiac Magnetic Resonance) showing any segment of the left ventricular wall with a thickness > 15 mm, without any other probable cause. Genetic analysis allows the identification of mutations in genes encoding different structures of the sarcomere responsible for the development of HCM in about 60% of cases, enabling screening of family members and genetic counseling, as an important part of patient and family management. Several concepts about HCM have recently been reviewed, including its prevalence of 1 in 250 individuals, hence not a rare but rather underdiagnosed disease. The vast majority of patients are asymptomatic. In symptomatic cases, obstruction of the left ventricular outflow tract (LVOT) is the primary disorder responsible for symptoms, and its presence should be investigated in all cases. In those where resting echocardiogram or Valsalva maneuver does not detect significant intraventricular gradient (> 30 mmHg), they should undergo stress echocardiography to detect LVOT obstruction. Patients with limiting symptoms and severe LVOT obstruction, refractory to beta-blockers and verapamil, should receive septal reduction therapies or use new drugs inhibiting cardiac myosin. Finally, appropriately identified patients at increased risk of sudden death may receive prophylactic measure with implantable cardioverter-defibrillator (ICD) implantation.La miocardiopatía hipertrófica (MCH) es una forma de enfermedad cardíaca de origen genético, caracterizada por el engrosamiento de las paredes ventriculares. El diagnóstico requiere la detección mediante métodos de imagen (Ecocardiograma o Resonancia Magnética Cardíaca) que muestren algún segmento de la pared ventricular izquierda con un grosor > 15 mm, sin otra causa probable. El análisis genético permite identificar mutaciones en genes que codifican diferentes estructuras del sarcómero responsables del desarrollo de la MCH en aproximadamente el 60% de los casos, lo que permite el tamizaje de familiares y el asesoramiento genético, como parte importante del manejo de pacientes y familiares. Varios conceptos sobre la MCH han sido revisados recientemente, incluida su prevalencia de 1 entre 250 individuos, por lo tanto, no es una enfermedad rara, sino subdiagnosticada. La gran mayoría de los pacientes son asintomáticos. En los casos sintomáticos, la obstrucción del tracto de salida ventricular izquierdo (TSVI) es el trastorno principal responsable de los síntomas, y su presencia debe investigarse en todos los casos. En aquellos en los que el ecocardiograma en reposo o la maniobra de Valsalva no detecta un gradiente intraventricular significativo (> 30 mmHg), deben someterse a ecocardiografía de esfuerzo para detectar la obstrucción del TSVI. Los pacientes con síntomas limitantes y obstrucción grave del TSVI, refractarios al uso de betabloqueantes y verapamilo, deben recibir terapias de reducción septal o usar nuevos medicamentos inhibidores de la miosina cardíaca. Finalmente, los pacientes adecuadamente identificados con un riesgo aumentado de muerte súbita pueden recibir medidas profilácticas con el implante de un cardioversor-desfibrilador implantable (CDI).A cardiomiopatia hipertrófica (CMH) é uma forma de doença do músculo cardíaco de causa genética, caracterizada pela hipertrofia das paredes ventriculares. O diagnóstico requer detecção por métodos de imagem (Ecocardiograma ou Ressonância Magnética Cardíaca) de qualquer segmento da parede do ventrículo esquerdo com espessura > 15 mm, sem outra causa provável. A análise genética permite identificar mutações de genes codificantes de diferentes estruturas do sarcômero responsáveis pelo desenvolvimento da CMH em cerca de 60% dos casos, permitindo o rastreio de familiares e aconselhamento genético, como parte importante do manejo dos pacientes e familiares. Vários conceitos sobre a CMH foram recentemente revistos, incluindo sua prevalência de 1 em 250 indivíduos, não sendo, portanto, uma doença rara, mas subdiagnosticada. A vasta maioria dos pacientes é assintomática. Naqueles sintomáticos, a obstrução do trato de saída do ventrículo esquerdo (OTSVE) é o principal distúrbio responsável pelos sintomas, devendo-se investigar a sua presença em todos os casos. Naqueles em que o ecocardiograma em repouso ou com Manobra de Valsalva não detecta gradiente intraventricular significativo (> 30 mmHg), devem ser submetidos à ecocardiografia com esforço físico para detecção da OTSVE.   Pacientes com sintomas limitantes e grave OTSVE, refratários ao uso de betabloqueadores e verapamil, devem receber terapias de redução septal ou uso de novas drogas inibidoras da miosina cardíaca. Por fim, os pacientes adequadamente identificados com risco aumentado de morta súbita podem receber medida profilática com implante de cardiodesfibrilador implantável (CDI)

Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants

Summary Background Comparable global data on health and nutrition of school-aged children and adolescents are scarce. We aimed to estimate age trajectories and time trends in mean height and mean body-mass index (BMI), which measures weight gain beyond what is expected from height gain, for school-aged children and adolescents. Methods For this pooled analysis, we used a database of cardiometabolic risk factors collated by the Non-Communicable Disease Risk Factor Collaboration. We applied a Bayesian hierarchical model to estimate trends from 1985 to 2019 in mean height and mean BMI in 1-year age groups for ages 5–19 years. The model allowed for non-linear changes over time in mean height and mean BMI and for non-linear changes with age of children and adolescents, including periods of rapid growth during adolescence. Findings We pooled data from 2181 population-based studies, with measurements of height and weight in 65 million participants in 200 countries and territories. In 2019, we estimated a difference of 20 cm or higher in mean height of 19-year-old adolescents between countries with the tallest populations (the Netherlands, Montenegro, Estonia, and Bosnia and Herzegovina for boys; and the Netherlands, Montenegro, Denmark, and Iceland for girls) and those with the shortest populations (Timor-Leste, Laos, Solomon Islands, and Papua New Guinea for boys; and Guatemala, Bangladesh, Nepal, and Timor-Leste for girls). In the same year, the difference between the highest mean BMI (in Pacific island countries, Kuwait, Bahrain, The Bahamas, Chile, the USA, and New Zealand for both boys and girls and in South Africa for girls) and lowest mean BMI (in India, Bangladesh, Timor-Leste, Ethiopia, and Chad for boys and girls; and in Japan and Romania for girls) was approximately 9–10 kg/m2. In some countries, children aged 5 years started with healthier height or BMI than the global median and, in some cases, as healthy as the best performing countries, but they became progressively less healthy compared with their comparators as they grew older by not growing as tall (eg, boys in Austria and Barbados, and girls in Belgium and Puerto Rico) or gaining too much weight for their height (eg, girls and boys in Kuwait, Bahrain, Fiji, Jamaica, and Mexico; and girls in South Africa and New Zealand). In other countries, growing children overtook the height of their comparators (eg, Latvia, Czech Republic, Morocco, and Iran) or curbed their weight gain (eg, Italy, France, and Croatia) in late childhood and adolescence. When changes in both height and BMI were considered, girls in South Korea, Vietnam, Saudi Arabia, Turkey, and some central Asian countries (eg, Armenia and Azerbaijan), and boys in central and western Europe (eg, Portugal, Denmark, Poland, and Montenegro) had the healthiest changes in anthropometric status over the past 3·5 decades because, compared with children and adolescents in other countries, they had a much larger gain in height than they did in BMI. The unhealthiest changes—gaining too little height, too much weight for their height compared with children in other countries, or both—occurred in many countries in sub-Saharan Africa, New Zealand, and the USA for boys and girls; in Malaysia and some Pacific island nations for boys; and in Mexico for girls. Interpretation The height and BMI trajectories over age and time of school-aged children and adolescents are highly variable across countries, which indicates heterogeneous nutritional quality and lifelong health advantages and risks

Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight NCD Risk Factor Collaboration (NCD-RisC)

From 1985 to 2016, the prevalence of underweight decreased, and that of obesity and severe obesity increased, in most regions, with significant variation in the magnitude of these changes across regions. We investigated how much change in mean body mass index (BMI) explains changes in the prevalence of underweight, obesity, and severe obesity in different regions using data from 2896 population-based studies with 187 million participants. Changes in the prevalence of underweight and total obesity, and to a lesser extent severe obesity, are largely driven by shifts in the distribution of BMI, with smaller contributions from changes in the shape of the distribution. In East and Southeast Asia and sub-Saharan Africa, the underweight tail of the BMI distribution was left behind as the distribution shifted. There is a need for policies that address all forms of malnutrition by making healthy foods accessible and affordable, while restricting unhealthy foods through fiscal and regulatory restrictions

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. Copyright (C) 2021 World Health Organization; licensee Elsevier

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

Kinetics characterization of-glucosidasic activities from Humicola insolen

Os materiais lignocelulósicos são os principais resíduos da atividade agroindustrial. Atualmente, é grande a procura por enzimas capazes de degradá-los, visando à produção de diversos compostos químicos, em especial combustíveis renováveis, como o etanol, com baixo impacto ambiental. A celulose é o polissacarídeo majoritário da parede celular das plantas e a macromolécula mais abundante produzida na Terra. A degradação enzimática da celulose é, portanto, de especial significado ambiental e comercial. A celulose é um polissacarídeo linear composto de unidades de glicose ligadas por ligações glicosídicas do tipo -(1,4). A hidrólise enzimática da celulose envolve pelo menos três classes de enzimas: endoglucanases, celobiohidrolases (exoglucanases) e -glucosidases. Apenas as duas primeiras enzimas agem diretamente sobre a celulose, depolimerizando as cadeias e liberando oligossacarídeos de diferentes tamanhos e celobiose. A celobiose é a unidade básica repetitiva da celulose e pode ser convertida em resíduos de glicose pelas -glucosidases. Este sistema enzimático funciona sinergisticamente, e as -glucosidases são responsáveis pelo passo terminal da sacarificação da celulose, liberando as endoglucanases e exoglucanases da inibição por celobiose. Entretanto, em sua grande maioria, as -glucosidases também são inibidas pelo produto da reação catalisada, o que vem despertando um interesse crescente por enzimas tolerantes à glicose. Resultados preliminares mostraram que, quando cultivado em meio líquido empregando avicel como fonte de carbono, o fungo termófilo Humicola insolens é um bom produtor de -glucosidases. Além disso, a atividade do extrato bruto micelial foi estimulada por glicose ou xilose. A análise eletroforética deste extrato bruto, em condições não desnaturantes, revelou ainda a presença de duas bandas de atividade ß-glucosidásica, sendo uma estimulada e outra inibida por glicose em concentração 100 mM. Este trabalho descreve a produção, purificação e caracterização bioquímica de duas -glucosidases miceliais de Humicola insolens. As melhores condições de cultivo para a produção de -glucosidase micelial foram 40°C, 120 rpm, em meio constituído de K2HPO4 0,1%, MgSO4.7H2O 0,05%, solução de traços de elementos (25 L para cada 50 mL de meio), extrato de levedura 0,8% e avicel 0,75%, em pH inicial 6,0. O tempo de cultivo para máxima produção foi de 4 dias. As duas -glucosidases miceliais, denominadas BGH I e BGH II, foram purificadas por um procedimento que envolveu precipitação com sulfato de amônio a 75%, seguida por dessalificação em Sephadex G-25, cromatografia de troca iônica em DEAE fractogel e filtração em gel de Sephacryl S-200. Após a purificação, BGH I atingiu uma atividade específica de 25 U/mg com um rendimento de 7,9% e fator de purificação 27,5 vezes. Já a forma BGH II apresentou atividade específica de 15,2 U/mg, com rendimento de 30% e fator de purificação 16,5 vezes. As enzimas apresentaram um conteúdo de carboidratos totais de 51 % (BGH I) e 21% p/p (BGH II). A forma BGH I apresentou massa molecular aparente, estimada por filtração em gel, de 282 kDa, enquanto para (BGH II) este valor foi de 94 kDa. A análise em SDS-PAGE de BGH II mostrou uma única banda protéica de 55 kDa, sugerindo que a forma nativa da enzima é um homodimero. Já para BGH I foram reveladas 3 bandas, com massa moleculares aparentes de 31 kDa, 52 kDa e 132 kDa, sugerindo uma estrutura tetramérica. Entretanto, considerando que se trata de uma enzima altamente glicosilada, estes resultados devem ser interpretados com cautela. Estudos de espectrometria de massas de BGH II demonstraram boa similaridade da sua seqüência de aminoácidos com aquela de uma -glucosidase de Humicola grisea var. thermoidea, com cerca de 22% de recobrimento. A temperatura ótima de reação foi de 60ºC para ambas as -glucosidases purificadas e os valores de pH ótimo foram 5,0 e 6,0 para BGH I e BGH II, respectivamente. Ambas as enzimas foram estáveis quando incubadas em água até 1 hora, a 50ºC; BGH I apresentou um tempo de meia-vida de 47 min a 60°C, enquanto BGH II apresentou um tempo de meia-vida de 40 min a 55°C. Quando incubadas em tampões de diferentes pH por 24 h, BGH I mostrou-se estável em uma faixa de 5-8 e BGH II em pH 6-8. A forma BGH I apresentou maior especificidade de substrato que BGH II, hidrolisando apenas p-nitrofenil-ß-D-glucopiranosídeo, celobiose e salicina, dentre todos os substratos testados. Já BGH II hidrolisou celobiose, lactose, p-nitrofenil-ß-D-glucopiranosideo, p-nitrofenil-ß-D-fucopiranosídeo, p-nitrofenil-ß-D-xilanopiranosídeo, p-nitrofenil-ß-D-galactopiranosídeo, o-nitrofenil-ß-Dgalactopiranosídeo e salicina. Nenhuma das duas enzimas hidrolisou substratos poliméricos (CMC e Avicel), além de maltose, trealose e sacarose. Estudos cinéticos mostraram que a forma BGH I hidrolisou p-nitrofenil-ß-D-glucopiranosídeo e celobiose com a mesma velocidade máxima (25 U/mg). Porém, a afinidade aparente da enzima foi cerca de 7 vezes maior para o substrato sintético. Já os melhores substratos para BGH II foram p-nitrofenil-ß-D-fucopiranosídeo (VM/KM = 323,3 U/mg.mM) e celobiose (VM/KM = 168,0 U/mg.mM). De maneira muito interessante, a atividade de BGH II foi ativada por glicose ou xilose até concentrações de 400 mM, com efeito estimulatório máximo de cerca de 2 vezes próximo a 100 mM. Em contraste, a atividade de BGH I foi inibida em 95% por glicose 50 mM. Concluindo, a grande eficiência catalítica para substratos naturais, sua boa estabilidade térmica, forte estimulação por glicose e xilose, e tolerância a elevadas concentrações destes monossacarídeos no meio reacional, qualificam a enzima BGH II para aplicação na hidrólise de resíduos celulósicos.Lignocellulosic materials are the major residues from agroindustrial activities. Currently, there is a great interest in enzymes able to degrade such residues, aiming the production of several chemical products, particularly renewable fuels like ethanol, with low environmental impact. Cellulose is the main polysaccharidic component of the plant cell wall and the most abundant naturally occurring macromolecule on Earth. The enzymatic degradation of cellulose is therefore of great environmental and commercial significance. Cellulose is a linear polysaccharide composed of glucose units, linked by -(1,4)-glycosidic bonds. The enzymatic hydrolysis of cellulose involves at least three types of enzymes: endoglucanases, cellobiohydrolases (exoglucanases), and glucosidases. Only the first two enzymes act directly on cellulose, depolymerizing the cellulose chains and releasing different oligosaccharides and cellobiose. Cellobiose is the basic repetitive unit of cellulose and can be converted into glucose monomers by -glucosidases. This enzymatic system works synergistically, and -Glucosidases are responsible for the terminal step of cellulose saccharification, releasing endoglucanases and cellobiohydrolases from cellobiose inhibition. However, most -Glucosidases are also inhibited by their reaction product, leading to a growing interest in glucose tolerant enzymes. Preliminary results showed that, when grown in liquid medium supplemented with microcrystalline cellulose (avicel®) as carbon source, the thermophilic fungus Humicola insolens is a good producer of -glucosidases. Moreover, the activity of the mycelial crude extract was stimulated by glucose or xylose. The electrophoretic analysis of this crude extract in non-denaturing conditions also revealed the presence of two bands of ß-glucosidase activity, one stimulated and the other inhibited by 100 mM glucose. This study describes the production, purification and biochemical characterization of two mycelial -glucosidases from Humicola insolens. Best culture conditions to mycelial -glucosidase production were 40°C, 120 rpm, in liquid media containing 0,1% K2HPO4, 0,05% MgSO4.7H2O, trace elements solution (25 L/50 mL medium), 0,8% yeast extract and 0,75% avicel, with initial pH adjusted to 6,0. The culture time for maximal production was 4 days. The experimental protocol for the simultaneous purification of both mycelial -glucosidases, named BGH I and BGH II, involved 75% amonium sulfate precipitation, followed by Sephadex G-25 desalting, DEAE-fractogel ion exchange chromatography and gel filtration in Sephacryl S-200. The form BGH I was purified 27.5 fold, reaching a specific activity of 25 U/mg with 7.9% yield. BGH II was purified 16.5 fold, with a yield of about 30% and the specific activity was 15.2 U/mg. The enzymes showed total carbohydrate content of 51% (BGH I) and 21% w/w (BGH II). The apparent molecular masses corresponded to 282 kDa (BGH I) and 94 kDa (BGH II), as estimated by gel filtration. Sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis of BGH II showed a single polypeptide band of 55 kDa, suggesting that the native enzyme is a homodimer. In contrast, three protein bands were revealed for BGH I, corresponding to apparent molecular masses of 31 kDa, 52 kDa e 132 kDa, suggesting a tetrameric structure. However, considering its high level of glycosylation, the results must be considered cautiously. Mass spectrometry analysis of BGH II showed good amino acid sequence similarity with a -glucosidase from Humicola grisea var. thermoidea, with about 22% coverag

Production of a xylose-stimulated beta-glucosidase and a cellulase-free thermostable xylanase by the thermophilic fungus Humicola brevis var. thermoidea under solid state fermentation

Humicola brevis var. thermoidea cultivated under solid state fermentation in wheat bran and water (1:2 w/v) was a good producer of beta-glucosidase and xylanase. After optimization using response surface methodology the level of xylanase reached 5,791.2 +/- A 411.2 U g(-1), while beta-glucosidase production was increased about 2.6-fold, reaching 20.7 +/- A 1.5 U g(-1). Cellulase levels were negligible. Biochemical characterization of H. brevis beta-glucosidase and xylanase activities showed that they were stable in a wide pH range. Optimum pH for beta-glucosidase and xylanase activities were 5.0 and 5.5, respectively, but the xylanase showed 80 % of maximal activity when assayed at pH 8.0. Both enzymes presented high thermal stability. The beta-glucosidase maintained about 95 % of its activity after 26 h in water at 55 A degrees C, with half-lives of 15.7 h at 60 A degrees C and 5.1 h at 65 A degrees C. The presence of xylose during heat treatment at 65 A degrees C protected beta-glucosidase against thermal inactivation. Xylanase maintained about 80 % of its activity after 200 h in water at 60 A degrees C. Xylose stimulated beta-glucosidase activity up to 1.7-fold, at 200 mmol L-1. The notable features of both xylanase and beta-glucosidase suggest that H. brevis crude culture extract may be useful to compose efficient enzymatic cocktails for lignocellulosic materials treatment or paper pulp biobleaching.Conselho de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho de Desenvolvimento Cientifico e Tecnologico (CNPq)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES